0.00Open0.00Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover400.13%IV-77.53%PremiumJan 17, 2025Expiry Date17.25Intrinsic Value100Multiplier21DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9793Delta0.0023Gamma1.27Leverage Ratio-0.0255Theta0.0025Rho1.24Eff Leverage0.0027Vega
Jasper Therapeutics Stock Discussion
Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria
14 of 15 participants enrolled achieved a clinical response
10 of 12 participants in the 120mg cohort achieved a complete response
No serious adverse events; no grade 3 or higher adverse events reported
Initial data from BEACON study expected week of January 6th, 2025, including 180mg Q8W cohort
Company to host conference call and webinar today at 8:00 ...
Microsoft $Microsoft (MSFT.US)$ (office currently has nearly 400 million users, OficARPU increases after the acquisition of OpenA and Azurez-related...
No comment yet